胰岛素激素激动剂:当前和新兴的肥胖管理药物疗法
Ibrahim S Alhomoud1, Azita H Talasaz2, Preethi Chandrasekaran3
1Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim, Saudi Arabia.
Pharmacotherapy
|September 3, 2024
概括
激素激素激动剂如利拉格卢提德和塞马格卢提德在肥胖管理方面提供了显著的减肥和健康益处. 新兴的双倍和三倍基激素激应剂显示出对治疗进一步进展的希望.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 肥胖影响全球超过8亿人,传统方法取得的成功有限.
- 腹腔外科手术是有效的,但由于风险,保留给严重病例.
- 药物治疗对于肥胖管理越来越重要.
研究的目的:
- 审查当前和新兴的肥胖因克列激素激动剂的机制和疗效.
- 为了突出体重管理药物治疗的进步.
主要方法:
- 对因克雷丁激动剂的关键临床试验 (SCALE,STEP,SURMOUNT-1) 的审查.
- 根据机制和施用途径对新型疗法进行分类.
- 讨论双重,三重和协同激动剂.
主要成果:
- 利拉格卢提德,塞马格卢提德和蒂尔泽帕提德显示出显著的减肥和心脏代谢益处.
- 新型疗法包括口服GLP-1激动剂,三重激动剂 (GLP-1/GIP/葡萄糖) 和协同激动剂.
- 目前正在进行的研究正在探索氨酸受体激动剂与GLP-1激动剂相结合.
结论:
- 基于因克雷丁的疗法代表了肥胖药物治疗的重大进步.
- 新兴的英克雷丁激动剂有可能改善临床结果并减少肥胖并发症.
- 预计持续的发展将加强肥胖管理策略.
相关概念视频
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
Oral Hypoglycemic Agents: Glinides
148
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
148
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Regulation of Food Intake
205
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
205


